Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies

Sattar, N; Valensi, P; Preiss, D; Dent, R; Bridges, I; Ruzza, A; Cyrille, M; Handelsman, Y

Conference item

Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Sattar, N., Valensi, P., Preiss, D., Dent, R., Bridges, I., Ruzza, A., Cyrille, M., & Handelsman, Y. (2016). Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies. 59(Supplement 1), S528.

MLA Style

Sattar, N, et al. “Long-Term Efficacy of Evolocumab in Reducing Lipids in EU Subjects with and without Type 2 Diabetes: an Analysis from the Open-Label Extension OSLER Studies.” vol. 59, no. Supplement 1, 2016, p. S528.

Chicago Style

Sattar, N, P Valensi, D Preiss, et al. 2016. “Long-Term Efficacy of Evolocumab in Reducing Lipids in EU Subjects with and without Type 2 Diabetes: an Analysis from the Open-Label Extension OSLER Studies.” 59 (Supplement 1): S528.
Print

Access Document

Files:: osler abstract easd.pdf

(Preview, Accepted manuscript, pdf, 26.2KB, Terms of use)

Publisher copy:: 10.1007/s00125-016-4046-9

Authors

+ Sattar, N More by this author

Role:: Author

+ Valensi, P More by this author

Role:: Author

+ Preiss, D More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: Clinical Trial Service Unit
Role:: Author
ORCID:: 0000-0003-3139-1836

+ Dent, R More by this author

Role:: Author

+ Bridges, I More by this author

Role:: Author

More authors...

Publisher:: Springer Verlag
Host title:: Diabetologia
Journal:: DIABETOLOGIA More from this journal
Volume:: 59
Issue:: Supplement 1
Pages:: S528
Publication date:: 2016-08-18
Acceptance date:: 2016-06-06
DOI:: 10.1007/s00125-016-4046-9
EISSN:: 1432-0428
ISSN:: 0012-186X

Pubs id:: pubs:722557
UUID:: uuid:88f41bfc-5c34-4c54-85c4-fb2cf385df9d
Local pid:: pubs:722557
Source identifiers:: 722557
Deposit date:: 2017-12-30
ARK identifier:: ark:/29072/ora_88f41bfc5c344c5485c4fb2cf385df9d

Terms of use

Notes:: This is the author accepted manuscript following peer review version of the article. The final version is available online from Springer Verlag at: 10.1007/s00125-016-4046-9

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

Conference item

Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies

Actions

Access Document

Authors

Terms of use

Views and Downloads

Altmetrics

Dimensions

Conference item

Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies

Actions

Access Document

Authors

Bibliographic Details

Item Description

Terms of use

Metrics

Views and Downloads

Altmetrics

Dimensions